Introduction to Idelalisib
Idelalisib, also known as Zydelig, is a medication used to treat certain types of cancer, including chronic lymphocytic leukemia and follicular lymphoma. It works by inhibiting the activity of a protein called PI3K, which is involved in the growth and survival of cancer cells.
The FDA approval history of Idelalisib is complex, with the medication receiving initial approval in 2014 for the treatment of relapsed chronic lymphocytic leukemia. Since then, the FDA has expanded the approved uses of Idelalisib to include other types of cancer.
FDA Approval History
Idelalisib was first approved by the FDA in July 2014 for the treatment of relapsed chronic lymphocytic leukemia. The approval was based on the results of a clinical trial that demonstrated the efficacy of Idelalisib in improving overall survival and progression-free survival in patients with this type of cancer.
In 2015, the FDA expanded the approved uses of Idelalisib to include the treatment of relapsed follicular lymphoma. This approval was based on the results of a clinical trial that demonstrated the efficacy of Idelalisib in improving overall survival and progression-free survival in patients with this type of cancer.
Regulatory Status
Idelalisib is currently approved by the FDA for the treatment of certain types of cancer, including chronic lymphocytic leukemia and follicular lymphoma. The medication is available in the United States under the brand name Zydelig, which is marketed by Gilead Sciences.
The regulatory status of Idelalisib is subject to change, as the FDA continues to review new data and evidence related to the safety and efficacy of the medication. Patients and healthcare providers should stay informed about any updates or changes to the regulatory status of Idelalisib.
Clinical Trials and Research
Idelalisib has been studied in numerous clinical trials, which have demonstrated its efficacy and safety in the treatment of certain types of cancer. Ongoing research is focused on exploring the potential uses of Idelalisib in other types of cancer, as well as its potential in combination with other medications.
The results of clinical trials and research studies have been published in various medical journals and presented at conferences, providing valuable information for healthcare providers and patients about the safety and efficacy of Idelalisib.
Conclusion
In conclusion, Idelalisib is a medication that has been approved by the FDA for the treatment of certain types of cancer, including chronic lymphocytic leukemia and follicular lymphoma. The regulatory status of Idelalisib is subject to change, and patients and healthcare providers should stay informed about any updates or changes.
Idelalisib has been shown to be effective in improving overall survival and progression-free survival in patients with certain types of cancer, and ongoing research is focused on exploring its potential uses in other types of cancer. As with any medication, it is essential to carefully review the potential benefits and risks of Idelalisib before initiating treatment.
Frequently Asked Questions
What is Idelalisib used to treat?
Idelalisib is used to treat certain types of cancer, including chronic lymphocytic leukemia and follicular lymphoma.
When was Idelalisib approved by the FDA?
Idelalisib was first approved by the FDA in July 2014 for the treatment of relapsed chronic lymphocytic leukemia.
What is the brand name of Idelalisib?
The brand name of Idelalisib is Zydelig, which is marketed by Gilead Sciences.
What are the potential side effects of Idelalisib?
The potential side effects of Idelalisib include diarrhea, fatigue, and nausea, among others. Patients should discuss the potential side effects with their healthcare provider.
Can Idelalisib be used in combination with other medications?
Yes, Idelalisib can be used in combination with other medications, but patients should discuss the potential benefits and risks with their healthcare provider.
Is Idelalisib available in the United States?
Yes, Idelalisib is available in the United States under the brand name Zydelig, which is marketed by Gilead Sciences.